BioAsia 2023: Leaders from Novartis, Apple Talk Innovation, Tech, Data Privacy
Executive Summary
BioAsia 2023 was a melting pot of ideas with Novartis's CEO and a senior executive from Apple, among others, discussing a range of topics including the potential of novel therapies and platforms such as siRNA and radioligand and also where things were headed as the union of technology and biotech drives new insights into biology and promises to help reimagine healthcare.
You may also be interested in...
McKinsey Exec On Generative AI in R&D And Pharmacovigilance, Digital Twins
McKinsey & Company's senior partner Vikas Bhadoria, in this first instalment of a wide-ranging two-part interview with Scrip, outlines a number of use cases to define where pharma currently is and the potential value that can be unlocked as industry adopts new technologies such as generative AI, digital twins and the metaverse.
ChatGPT Unleashed: Generative AI Use Cases Taking Off In Pharma
As generative AI and its star avatar, ChatGPT, take the world by storm, pharma is seeing traction for use cases around smarter pharmacovigilance and commercial marketing content development, among others. Senior executives from Indegene discuss this and more in an interview with Scrip.
Big Pharma R&D Chiefs On IRA’s Unintended Casualty, Product Life Cycle Compression
R&D heads of Takeda, Amgen, Lilly and Novartis discuss some of the tectonic forces shaping the biopharma sector and the unintended consequences of the IRA on small molecule innovation. Advances in the neurodegenerative diseases segment amid impressive data from donanemab was another key talking point.